scispace - formally typeset
R

Raul D. Santos

Researcher at University of São Paulo

Publications -  463
Citations -  21660

Raul D. Santos is an academic researcher from University of São Paulo. The author has contributed to research in topics: Familial hypercholesterolemia & Medicine. The author has an hindex of 56, co-authored 404 publications receiving 16997 citations. Previous affiliations of Raul D. Santos include Albert Einstein Hospital.

Papers
More filters
Journal ArticleDOI

Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management

TL;DR: As compared to the North American Guideline, the V Brazilian Guideline considers a substantially higher proportion of the population as eligible for statin use in primary prevention, particularly because of the risk reclassification based on aggravating factors.
Journal ArticleDOI

The association between coronary artery calcification progression and loss of bone density in non-dialyzed CKD patients.

TL;DR: Investigation of the progression of CAC was associated with overtime reduction in bone density in non-dialyzed CKD patients revealed loss of VBD as the independent determinant of Cac progression in these patients.
Journal ArticleDOI

Familial hypercholesterolemia and cardiovascular disease in older individuals.

TL;DR: In this paper, the authors compared characteristics of genetically defined hypercholesterolemia (FH) older individuals with age-matched non-FH counterparts and found that the genetic diagnosis of FH was associated with higher ASCVD rates.
Journal ArticleDOI

Past, Present, and Future of Familial Hypercholesterolemia Management

TL;DR: While it is possible to normalize LDL-C in people with FH, the disease unfortunately is still severely underdiagnosed and undertreated.
Journal ArticleDOI

Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey

TL;DR: This survey of physicians in Japan, Germany, Colombia and the Philippines has identified key gaps in knowledge about dyslipidaemia management that relate to the safety of low LDL-C levels, theSafety of statins, and lipid management of chronic kidney disease.